Navigation Links
Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
Date:10/11/2010

SAN DIEGO, Oct. 11 /PRNewswire/ -- Essentialis, Inc. announced today that the United States Patent & Trademark Office (USPTO) has issued U.S. Patent No. 7,799,777 entitled Salts of potassium ATP channel openers and uses thereof. The patent claims a novel composition of a polymorph of diazoxide choline, the active ingredient in the Essentialis lead product, DCCR.  Essentialis has successfully completed phase 2b clinical trials with DCCR, showing a highly significant triglyceride reduction in dyslipidemic patients.

"The granting of this patent further secures our intellectual property position on the active component in DCCR", said Aaron Berg, Chief Commercial Officer of Essentialis.  "This patent combined with our previously issued patents provide Essentialis with broad patent protection on our drug active, pharmaceutical formulations, methods of use and methods of manufacturing DCCR which currently extends to 2028."  

DCCR is the first product in a new class of dyslipidemia treatment, with a mechanism of action distinct from other dyslipidemia treatments.  In Phase 2b clinical studies, DCCR has demonstrated the potential to lower triglycerides (30-50%), non-HDL cholesterol and Apo B (10-15%) while raising HDL-cholesterol (5-10%). DCCR reduces the production of triglyceride rich lipoprotein particles before they can accumulate and contribute to the progression of pancreatitis and cardiovascular disease. Currently available dsylipidemia treatments (such as fibrates and omega 3 fatty acid products) work primarily by increasing clearance of triglycerides from the blood stream.

"DCCR's unique mechanism of action will allow for additive efficacy with statins and other lipid-lowering agents to better achieve desired lipid targets," said Neil Cowen, Ph.D., Co-founder and Chief Scientific Officer for Essentialis.  "Once a patient maximizes their benefit from one agent, additional therapeutic benefit may be achieved with DCCR, helping them reach lipid goals."

Patients taking DCCR experience mostly mild to moderate, transient adverse events, the most frequent of which included increases in fasting plasma glucose that are similar to or less than those seen with niacin, another lipid-lowering drug, peripheral edema similar to what is seen with calcium channel blocking antihypertensives, and headaches.

About Very High Triglycerides

Hypertriglyceridemia, a disease where patients have high blood levels of triglycerides, is associated with increased risk of coronary heart disease even after LDL-cholesterol targets have been achieved. Very high triglycerides are associated with an increased risk of developing pancreatitis. There are approximately 4 million patients in the US with very high triglycerides. The leading products for treating very high triglycerides, Lovaza® and fenofibrate, while effective, also cause significant elevations in LDL-cholesterol.

About Essentialis

Essentialis is a pharmaceutical company based in San Diego, CA focused on the development of breakthrough medicines for the treatment of cardiovascular and metabolic diseases. The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases.


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis to Submit SPA for Hypertriglyceridemia
2. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
3. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
4. American Medical Systems Strengthens Global Expansion With GreenLight HPS® Acquisitions in Australia
5. PAREXEL Opens New Office in Japan and Further Strengthens Leading Presence in Asia/Pacific Region
6. Webmedx Strengthens Quality Program and Improves Patient Safety in Compliance with New Industry Standards for Clinical Documentation
7. Pepscan Therapeutics Strengthens Management Team
8. Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo
9. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
10. Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering
11. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... The global immunomodulators market is expected ... to a new study by Grand View Research, ... driven by high R&D investments employed by the ... new and therapeutically advanced drugs. This is believed ... unprecedented rate into the immunomodulators market hence providing ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
(Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
Breaking Medicine Technology:
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting ... family, friends, and community. “Coming Home 2017” will be held on Friday ...
(Date:1/20/2017)... ... ... New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift is ... be wheeled out of the way and stored when not in use. It is freestanding ... feedback from customers into specific enhancements and created a new product that is built directly ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Bionic Sports Nutrition ... walks of life, announced it had a successful January ECRM Trade Show in Hilton ... the United States, which allows it to provide its products to all clients at ...
(Date:1/20/2017)... ... , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are ... Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 ... flare and light leak transitions have a very high-dynamic range for super smooth falloff. ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how ... You” is the creation of published author, Stephen Miller, who, for over ten long years ... given to him. Born in Trinidad and Tobago, he has been serving the Lord for ...
Breaking Medicine News(10 mins):